Understanding the immune environment in gastroesophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the immune tumor microenvironment in patients with resectable gastric and gastroesophageal junction adenocarcinomas undergoing standard neoadjuvant chemotherapy. It will involve monitoring minimal residual disease (MRD) during both neoadjuvant and adjuvant therapy phases. The study will collect data from patients treated at Centre Léon Bérard, focusing on the immune response and its implications for treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patient \> 18 years of age on day of signing informed consent.
* Histologically proven non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III to be treated with standard neoadjuvant treatment.
* Surgery of primary tumor to be done at Centre Léon Bérard.
* Availability of archival FFPE tumor block from initial diagnosis with at least 20% of tumor cells.
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2.
* Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
* Patients must be covered by a medical insurance.

Exclusion Criteria:

* Any condition contraindicated with blood sampling procedures required by the protocol.
* Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer
* Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
* Pregnant or breast-feeding woman.

Where it's running

• Centre Léon Bérard
  Lyon, France Recruiting

Study contacts

• Principal investigator: Clélia COUTZAC, MD — Centre Leon Berard
• Study coordinator: Clélia COUTZAC, MD
• Email: clelia.coutzac@lyon.unicancer.fr
• Phone: 04 78 78 60 20

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• First-in-human dose study of DA-3501 for CLDN18.2-positive stomach, GEJ cancer, and pancreatic cancer

  A first-in-human study tests DA-3501 in adults with CLDN18.2-positive advanced stomach/GEJ cancer or pancreatic cancer to find a safe, effective dose.

  Recruiting at 3 sites Phase 1 Dong-A ST Co., Ltd. · Seongnam, Bundang and 2 other locations · NCT07481357

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Pulsed low-dose-rate radiation plus chemotherapy versus standard chemoradiation for esophageal cancer

  This trial will test whether delivering radiation as pulsed low-dose-rate together with chemotherapy reduces serious esophagitis compared with standard chemoradiation in adults with locally advanced esophageal adenocarcinoma.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT06906887

• Evaluating zanidatamab for HER2-expressing tumors

  This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.

  Recruiting at 30 sites Phase 2 Jazz Pharmaceuticals · Prescott, Arizona and 41 other locations · NCT06695845

• Support program for patients with gastroesophageal cancer

  This study tests if a special support program with nutrition help can improve the health of patients with gastroesophageal cancer compared to regular care during their treatment.

  Recruiting at 2 sites H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 1 other locations · NCT06497569

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.